The Journal of Immunology, Vol 150, Issue 11 4900-4910, Copyright © 1993 by American Association of Immunologists

ARTICLES

Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice

A Yoshimura, H Shiku and E Nakayama
Department of Periodontology, Nagasaki University School of Dentistry, Japan.

FBL-3N is an MHC class II Ag+ variant line that was obtained spontaneously during maintenance of Friend virus-induced leukemia FBL-3 in an athymic C57BL/6 (B6) mouse. Inocula of FBL-3N, but not the parental FBL-3 tumor, regressed after initial growth in CD8-depleted, syngeneic B6 mice. The cellular mechanisms by which FBL-3N was rejected in these mice were investigated in this study. We demonstrated that CTL with both CD4+ and CD4-CD8-TCR-alpha beta phenotypes were generated in mixed lymphocyte tumor cell culture spleen cells obtained from CD8- depleted B6 mice that had rejected FBL-3N by in vitro stimulation with mitomycin C-treated FBL-3N. After adoptive transfer of these CTL that were generated in vitro into athymic B6 mice, challenge with the FBL-3N tumor resulted in tumor regression after its initial growth. Thus, CD4+ and CD4-CD8-TCR-alpha beta CTL mediated rejection of the FBL-3N tumor in CD8-depleted B6 mice. Furthermore, the findings that depletion of B6 mice of CD4+ cells in addition to CD8+ cells abrogated the rejection of FBL-3N and generation of CTL in mixed lymphocyte tumor cell culture spleen cells suggest that CD4+ cells were required not only as a source of CD4+ CTL, but also as helper cells for generation of CD4-CD8-TCR- alpha beta CTL. Tumor Ag recognition of CD4-CD8-TCR-alpha beta CTL was restricted to Db, like that of classical CD8+ CTL, but the restriction appeared to be less obligatory than that of CD8+ CTL.

This article has been cited by other articles:

				D. S. Dace, P. W. Chen, H. Alizadeh, and J. Y. Niederkorn Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner J. Leukoc. Biol., February 1, 2007; 81(2): 421 - 429. [Abstract] [Full Text] [PDF]

				P. J. Norris, H. F. Moffett, O. O. Yang, D. E. Kaufmann, M. J. Clark, M. M. Addo, and E. S. Rosenberg Beyond Help: Direct Effector Functions of Human Immunodeficiency Virus Type 1-Specific CD4+ T Cells J. Virol., August 15, 2004; 78(16): 8844 - 8851. [Abstract] [Full Text] [PDF]

				N. Iwanami, A. Niwa, Y. Yasutomi, N. Tabata, and M. Miyazawa Role of Natural Killer Cells in Resistance against Friend Retrovirus-Induced Leukemia J. Virol., April 1, 2001; 75(7): 3152 - 3163. [Abstract] [Full Text]

				G. L. Beatty and Y. Paterson IFN-{{gamma}}-Dependent Inhibition of Tumor Angiogenesis by Tumor-Infiltrating CD4+ T Cells Requires Tumor Responsiveness to IFN-{{gamma}} J. Immunol., February 15, 2001; 166(4): 2276 - 2282. [Abstract] [Full Text] [PDF]

				C. N. Baxevanis, I. F. Voutsas, O. E. Tsitsilonis, A. D. Gritzapis, R. Sotiriadou, and M. Papamichail Tumor-Specific CD4+ T Lymphocytes from Cancer Patients Are Required for Optimal Induction of Cytotoxic T Cells Against the Autologous Tumor J. Immunol., April 1, 2000; 164(7): 3902 - 3912. [Abstract] [Full Text] [PDF]

				G. Perrin, V. Schnuriger, A.-L. Quiquerez, P. Saas, C. Pannetier, N. de Tribolet, J.-M. Tiercy, J.-P. Aubry, P.-Y. Dietrich, and P. R. Walker Astrocytoma infiltrating lymphocytes include major T cell clonal expansions confined to the CD8 subset Int. Immunol., August 1, 1999; 11(8): 1337 - 1350. [Abstract] [Full Text] [PDF]

				S. Onizuka, I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama Tumor Rejection by in Vivo Administration of Anti-CD25 (Interleukin-2 Receptor {{alpha}}) Monoclonal Antibody Cancer Res., July 1, 1999; 59(13): 3128 - 3133. [Abstract] [Full Text] [PDF]

				F. Ossendorp, E. Mengede, M. Camps, R. Filius, and C. J.M. Melief Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors J. Exp. Med., March 2, 1998; 187(5): 693 - 702. [Abstract] [Full Text] [PDF]